"The voice for cancer physicians and their patients in Massachusetts."

FDA APPROVES PERTUZUMAB FOR USE IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY

08 Jan 2018 2:25 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug administration granted regular approval to pertuzumab (Perjeta; Genentech) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software